心臓手術器具の日本市場（2025年～2033年）

日本の心臓手術器具の市場規模は、2024年に8,268万米ドルに達し、2033年までに1億6,665万米ドルに達すると予測され、予測期間の2025年～2033年にCAGRで8.1%の成長が見込まれます。

心臓手術器具は、心臓外科医が心臓や大きな血管に対して複雑な手技を行うのを支援するために設計された、高度に専門化されたツールです。これらの器具は、デリケートな組織の操作、正確な切開、縫合の固定を助けることから、手術中の精密さ、コントロール、安全性を確保するために不可欠です。心臓手術では、動脈、弁、心室などの構造を注意深く扱うことをたびたび求められるため、これらの器具は手術効率を高め、合併症を減らす上で重要な役割を担っています。

これらのツールは、冠動脈バイパス手術（CABG）、心臓弁の修復や置換、心臓移植、先天性心疾患の修正などのさまざまな重要な手術で使用されています。これらの手術にはそれぞれ、血管クランプ、リトラクター、鉗子、持針器など、手技の複雑性に合わせた特定の器具が必要です。ロボット支援や低侵襲ツールを含む心臓手術器具の継続的な進歩は、回復時間の短縮や術後リスクの最小化によって患者の転帰をさらに向上させています。

市場力学

促進要因と抑制要因

心血管疾患の罹患率の上昇

日本の心血管疾患（CVD）の有病率の増加は、心臓手術器具の需要を促進する大きな要因です。日本は世界有数の高齢化社会であり、国民の28%超が65歳以上であるため、冠動脈疾患（CAD）、心不全、弁膜症などの心臓疾患にかかりやすいです。

2024年に発表された研究によると、日本では心不全の有病率が上昇しており、2030年までに130万人に達すると予測され、このことは日本の心臓手術器具市場を大きく牽引しています。心不全がより一般的になるにつれて、冠動脈バイパス手術（CABG）、心臓弁修復/置換術、その他の心臓手術を含む心臓手術の需要が増加します。これは、心不全患者の治療と生活の質の向上を目的とした特殊な手術器具の必要性に直接影響します。

ライフスタイル要因によるCVDの負担の増加は、診断と治療の向上もあり、日本における心臓手術器具の需要を大きく促進しています。外科手術や低侵襲手術を受ける患者が増えるにつれて、病院や手術センターは最先端のツールに投資しており、このことが市場の成長をさらに後押ししています。

先進の手術器具の高いコスト

先進の手術器具の高いコストは、日本の心臓手術器具市場における大きな抑制要因となっています。これは、ロボット支援システムや低侵襲器具のような技術に特に当てはまり、これらは精度の向上と回復時間の短縮を提供しますが、かなりの高値が付きます。これらの先進技術に必要な初期投資は法外に高額な場合があり、特にすでに限られた予算で経営されている小規模の病院や医療センターにとってはなおさらです。地域によっては、初期費用が高いため、病院がこうした最先端のツールを広く採用することが難しい場合もあります。

日本の6つの病院で行われた経皮的冠動脈形成術（PTCA）のコスト分析によると、手術1件あたりの人件費は65,000円～98,000円でした。このことは、心臓インターベンションに必要な財政的負担の大きさを明示しています。さらに、使い捨て材料にかかるコストは手術1件あたり1,000円～39,000円と幅があり、人件費、材料費、器具投資を含めた合計コストは95,000円～224,000円でした。これらのコストのばらつきは、地域の予算上の制約や病院間の財政的な優先順位の違いが、いかに先進技術への投資能力に影響を与え、その採用や臨床への統合を制限しているかを反映しています。

当レポートでは、日本の心臓手術器具市場について調査し、市場力学、地域とセグメントの分析、競合情勢、企業プロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブインサイトと重要事項

• 市場のハイライトと戦略的ポイント
• 主要動向と将来の予測
• 抜粋：製品タイプ別
• 抜粋：用途別
• 抜粋：エンドユーザー別

第3章 市場力学

• 影響要因
  • 促進要因
    • 心血管疾患の罹患率の上昇
    • 心臓手術における技術的進歩
  • 抑制要因
    • 先進の手術器具の高いコスト
    • 厳格な規制要件
  • 機会
    • 低侵襲手術の需要の増加
  • 影響の分析

第4章 戦略的考察と産業の見通し

• マーケットリーダーとパイオニア
  • 新興パイオニアと著名企業
  • 最大の売上を誇るブランドを持つ確立されたリーダー
  • 確立された製品を持つマーケットリーダー
• CXOの視点
• 最新の発展とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大に対し推奨される戦略
• シナリオ分析：ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第5章 日本の心臓手術器具市場：製品タイプ別

• 手術器具
  • 鉗子
  • クランプ
  • メス
  • ハサミ
  • 持針器
  • その他
• 心臓モニタリング器具
• 冠動脈バイパス手術（CABG）器具
• 心臓弁修復・置換器具
• 内視鏡、ロボット器具
• 心肺バイパス器具
• その他

第6章 日本の心臓手術器具市場：用途別

• 冠動脈バイパス手術
• 心臓弁手術
• 小児手術
• 心臓移植
• その他

第7章 日本の心臓手術器具市場：エンドユーザー別

• 病院、心臓センター
• 外来手術センター
• その他

第8章 競合情勢と市場ポジショニング

• 競合情勢の概要、主要市場企業
• 市場シェア分析、ポジショニングマトリクス
• 戦略的パートナーシップ、合併・買収
• 製品ポートフォリオにおける主な発展、イノベーション
• 企業ベンチマーク

第9章 企業プロファイル

• Medtronic
• Johnson & Johnson (Ethicon)
• Abbott.
• Siemens Healthineers
• GE Healthcare
• Boston Scientific Corporation
• Terumo Cardiovascular Systems Corporation.
• Stryker
• Koninklijke Philips NV
• Edwards Lifesciences Corporation.

第10章 前提条件と調査手法

第11章 付録

The Japan cardiac surgery instruments market reached US$ 82.68 million in 2024 and is expected to reach US$ 166.65 million by 2033, growing at a CAGR of 8.1 % during the forecast period 2025-2033.

Cardiac surgery instruments are highly specialized tools designed to assist cardiothoracic surgeons in performing complex procedures on the heart and major blood vessels. These instruments are essential for ensuring precision, control, and safety during surgery, as they help manipulate delicate tissues, make accurate incisions, and secure sutures. Since heart surgeries often require meticulous handling of structures like arteries, valves, and chambers, these instruments play a crucial role in improving surgical efficiency and reducing complications.

These tools are used in a variety of critical procedures, including coronary artery bypass grafting (CABG), heart valve repair or replacement, heart transplants, and congenital heart defect corrections. Each of these surgeries demands specific instruments tailored to the procedure's complexity, such as vascular clamps, retractors, forceps, and needle holders. The continuous advancement of cardiac surgery instruments, including robotic-assisted and minimally invasive tools, has further enhanced patient outcomes by reducing recovery times and minimizing post-operative risks.

Market Dynamics: Drivers & Restraints

Rising Incidence of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases (CVDs) in Japan is a major factor driving demand for cardiac surgery instruments. Japan has one of the world's oldest populations, with over 28% of its residents aged 65 and older, making them more susceptible to heart diseases such as coronary artery disease (CAD), heart failure, and valve disorders.

According to the research study published in 2024, the rising prevalence of heart failure in Japan, projected to reach 1.3 million cases by 2030, is significantly driving the Japan cardiac surgery instruments market. As heart failure becomes more common, the demand for cardiac surgeries including coronary artery bypass grafting (CABG), heart valve repairs/replacements, and other heart surgeries increases. This directly impacts the need for specialized surgical instruments designed to treat heart failure patients and improve their quality of life.

The increasing burden of CVDs due to lifestyle factors, coupled with improvements in diagnosis and treatment, is significantly driving the demand for cardiac surgery instruments in Japan. As more patients undergo surgical and minimally invasive procedures, hospitals and surgical centers are investing in cutting-edge tools, which is further boosting the growth of the market.

High Cost of Advanced Surgical Instruments

The high cost of advanced surgical instruments is a major constraint in the Japanese cardiac surgery instruments market. This is particularly true for technologies like robotic-assisted systems and minimally invasive devices, which offer improved precision and faster recovery times but come with a significant price tag. The initial investment required for these advanced technologies can be prohibitively expensive, especially for smaller hospitals or healthcare centers that are already working with limited budgets. In certain regions, the high upfront costs make it challenging for hospitals to widely adopt these cutting-edge tools.

A cost analysis of percutaneous transluminal coronary angioplasty (PTCA) performed at six Japanese hospitals showed that labor costs ranged from yen 65,000 to yen 98,000 per procedure. This highlights the significant financial commitment required for cardiac interventions. In addition, the costs for disposable materials varied from yen 1,000 to yen 39,000 per procedure, bringing the total cost including labor, materials, and capital investment to between yen 95,000 and yen 224,000. The variation in these costs reflects how regional budget constraints and differing financial priorities among hospitals can impact their ability to invest in advanced technologies, limiting their adoption and integration into clinical practices.

Segment Analysis

The Japan cardiac surgery instruments market is segmented based on product type, application, and end-user.

Product Type:

The coronary artery bypass grafting (CABG) segment in the product type is expected to dominate Japan cardiac surgery instruments market share

The coronary artery bypass grafting (CABG) segment is a critical component of the Japan cardiac surgery instruments market, driven by the high prevalence of coronary artery disease (CAD) in the country. CABG is one of the most common cardiac surgical procedures, used to treat severe cases of CAD where coronary arteries become narrowed or blocked, restricting blood flow to the heart muscle. This procedure is typically required when other treatments, such as medication or angioplasty, are not sufficient to restore normal blood flow.

Furthermore, key players in the industry product launches drive this segment's growth in the Japan cardiac surgery instruments market. For instance, in August 2024, DePuy Synthes, the orthopedics division of Johnson & Johnson and part of Johnson & Johnson MedTech, launched the MatrixSTERNUM Fixation System. This plate and screw fixation system is specifically designed to stabilize and secure the front part of the chest wall after surgeries like open-heart surgery and thoracic surgery. The MatrixSTERNUM system addresses a critical need in the cardiac and thoracic surgery market by offering a more efficient and effective solution for post-surgical stabilization.

The introduction of advanced systems like the MatrixSTERNUM Fixation System is driving innovation in the Japan cardiac surgery instruments market. As Japan experiences an increasing number of cardiac and thoracic surgeries, hospitals are seeking more efficient, reliable, and patient-friendly solutions for surgical stabilization. These factors have solidified the segment's position in the Japan cardiac surgery instruments market.

Competitive Landscape

The major players in the Japan cardiac surgery instruments market include Medtronic, Johnson & Johnson (Ethicon), Abbott., Siemens Healthineers, GE Healthcare, Boston Scientific Corporation, Terumo Cardiovascular Systems Corporation., Stryker, Koninklijke Philips N.V., and Edwards Lifesciences Corporation among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan cardiac surgery instruments market report delivers a detailed analysis with 40+ key tables, more than 30 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by Application
• 2.5. Snippet by End-User

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Rising Incidence of Cardiovascular Diseases
    • 3.1.1.2. Technological Advancements in Cardiac Surgery
  • 3.1.2. Restraints
    • 3.1.2.1. High Cost of Advanced Surgical Instruments
    • 3.1.2.2. Stringent Regulatory Requirements
  • 3.1.3. Opportunity
    • 3.1.3.1. Rising Demand for Minimally Invasive Surgery
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest-selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
• 4.6. Porter's Five Forces Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Japan Cardiac Surgery Instruments Market, By Product Type

• 5.1. Introduction
  • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index, By Product Type
• 5.2. Surgical Instruments*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Forceps
  • 5.2.4. Clamps
  • 5.2.5. Scalpels
  • 5.2.6. Scissors
  • 5.2.7. Needle Holders
  • 5.2.8. Others
• 5.3. Cardiac Monitoring Instruments
• 5.4. Coronary Artery Bypass Grafting (CABG) Instruments
• 5.5. Heart Valve Repair & Replacement Instruments
• 5.6. Endoscopic and Robotic Instruments
• 5.7. Cardiopulmonary Bypass Equipment
• 5.8. Others

6. Japan Cardiac Surgery Instruments Market, By Application

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 6.1.2. Market Attractiveness Index, By Application
• 6.2. Coronary Artery Bypass Grafting*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Heart Valve Surgery
• 6.4. Pediatric Surgery
• 6.5. Heart Transplant
• 6.6. Others

7. Japan Cardiac Surgery Instruments Market, By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals and Cardiac Centers*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Ambulatory Surgery Centers
• 7.4. Others

8. Competitive Landscape and Market Positioning

• 8.1. Competitive Overview and Key Market Players
• 8.2. Market Share Analysis and Positioning Matrix
• 8.3. Strategic Partnerships, Mergers & Acquisitions
• 8.4. Key Developments in Product Portfolios and Innovations
• 8.5. Company Benchmarking

9. Company Profiles

• 9.1. Medtronic *
  • 9.1.1. Company Overview
  • 9.1.2. Product Portfolio
    • 9.1.2.1. Product Description
    • 9.1.2.2. Product Key Performance Indicators (KPIs)
    • 9.1.2.3. Historic and Forecasted Product Sales
    • 9.1.2.4. Product Sales Volume
  • 9.1.3. Financial Overview
    • 9.1.3.1. Company Revenue's
    • 9.1.3.2. Geographical Revenue Shares
    • 9.1.3.3. Revenue Forecasts
  • 9.1.4. Key Developments
    • 9.1.4.1. Mergers & Acquisitions
    • 9.1.4.2. Key Product Development Activities
    • 9.1.4.3. Regulatory Approvals, etc.
  • 9.1.5. SWOT Analysis
• 9.2. Johnson & Johnson (Ethicon)
• 9.3. Abbott.
• 9.4. Siemens Healthineers
• 9.5. GE Healthcare
• 9.6. Boston Scientific Corporation
• 9.7. Terumo Cardiovascular Systems Corporation.
• 9.8. Stryker
• 9.9. Koninklijke Philips N.V.
• 9.10. Edwards Lifesciences Corporation.

LIST NOT EXHAUSTIVE

10. Assumption and Research Methodology

• 10.1. Data Collection Methods
• 10.2. Data Triangulation
• 10.3. Forecasting Techniques
• 10.4. Data Verification and Validation

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us